Center for Disease Prevention Research, Medical College of Wisconsin, Milwaukee, Wisconsin.
Department of Pharmacology & Toxicology, Medical College of Wisconsin, Milwaukee, Wisconsin.
Cancer Prev Res (Phila). 2021 Mar;14(3):285-306. doi: 10.1158/1940-6207.CAPR-20-0425. Epub 2020 Dec 10.
Cancer chemoprevention is the most effective approach to control cancer in the population. Despite significant progress, chemoprevention has not been widely adopted because agents that are safe tend to be less effective and those that are highly effective tend to be toxic. Thus, there is an urgent need to develop novel and effective chemopreventive agents, such as mitochondria-targeted agents, that can prevent cancer and prolong survival. Mitochondria, the central site for cellular energy production, have important functions in cell survival and death. Several studies have revealed a significant role for mitochondrial metabolism in promoting cancer development and progression, making mitochondria a promising new target for cancer prevention. Conjugating delocalized lipophilic cations, such as triphenylphosphonium cation (TPP+), to compounds of interest is an effective approach for mitochondrial targeting. The hyperpolarized tumor cell membrane and mitochondrial membrane potential allow for selective accumulation of TPP conjugates in tumor cell mitochondria versus those in normal cells. This could enhance direct killing of precancerous, dysplastic, and tumor cells while minimizing potential toxicities to normal cells.
癌症化学预防是控制人群中癌症的最有效方法。尽管取得了重大进展,但化学预防尚未得到广泛采用,因为安全的药物往往效果较差,而效果好的药物往往毒性较大。因此,迫切需要开发新型有效的化学预防剂,如靶向线粒体的药物,以预防癌症和延长生存时间。线粒体是细胞能量产生的中心部位,在细胞存活和死亡中具有重要功能。几项研究表明,线粒体代谢在促进癌症发展和进展方面起着重要作用,使线粒体成为癌症预防的一个有前途的新靶点。将非定域亲脂阳离子(如三苯基膦阳离子(TPP+))与感兴趣的化合物结合是靶向线粒体的有效方法。极化肿瘤细胞膜和线粒体膜电位允许 TPP 缀合物选择性地在肿瘤细胞线粒体中积累,而不是在正常细胞中积累。这可以增强对癌前、发育不良和肿瘤细胞的直接杀伤作用,同时最大限度地减少对正常细胞的潜在毒性。
Cancer Prev Res (Phila). 2021-3
Drug Discov Today. 2024-6
Cancers (Basel). 2023-1-21
Neoplasma. 2020-2-28
Expert Opin Ther Targets. 2023
Clin Pharmacol. 2025-6-10
Bioact Mater. 2025-3-13
Pharmaceuticals (Basel). 2025-2-14
Transl Cancer Res. 2024-12-31
Front Immunol. 2019-12-11
Expert Opin Drug Deliv. 2019-12-10
Bioorg Med Chem Lett. 2019-9-6